Telix Pharmaceuticals

Telix Pharmaceuticals

Develops targeted radiation therapies for cancer

About Telix Pharmaceuticals

Simplify's Rating
Why Telix Pharmaceuticals is rated
A-
Rated B on Competitive Edge
Rated A on Growth Potential
Rated A on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

501-1,000

Company Stage

IPO

Headquarters

Melbourne, Australia

Founded

2015

Overview

Telix Pharmaceuticals develops and sells therapeutic and diagnostic products that use targeted radiation to improve the diagnosis and treatment of cancer and rare diseases. Their products work by delivering precise radiation to affected areas, which helps healthcare providers make better treatment decisions and offers personalized therapy options for patients. Unlike many other biopharmaceutical companies, Telix focuses specifically on areas such as urologic oncology, neuro-oncology, musculoskeletal oncology, and bone marrow conditioning, addressing significant unmet medical needs in these fields. The company's goal is to enhance patient care while maintaining a commitment to sustainability and ethical practices, ensuring that they create value for patients, shareholders, and employees.

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA's Priority Review for TLX250-CDx could lead to rapid market entry in 2025.
  • Illuccix's approval in the UK and Europe boosts Telix's position in prostate cancer imaging.
  • Acquisition of ImaginAb's platform expands Telix's pipeline into new therapeutic areas.

What critics are saying

  • Increased competition in radiopharmaceuticals may impact Telix's market share and pricing power.
  • Supply chain vulnerabilities could disrupt production and distribution of critical radioisotopes.
  • Regulatory hurdles may delay approvals, affecting Telix's product launch timelines.

What makes Telix Pharmaceuticals unique

  • Telix focuses on molecularly-targeted radiation therapy for prostate, renal, and glioblastoma cancers.
  • The company integrates sustainability and ethical practices into its operations and patient care.
  • Telix's global supply chain ensures product availability and delivery worldwide.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$14.8M

Above

Industry Average

Funded Over

4 Rounds

Post IPO Convertible funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Convertible Funding Comparison
Coming Soon

Benefits

Annual Performance Bonus

Equity-Based Incentive Program

Paid Vacation

Paid Wellness Days

Hybrid Work Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-2%
PR Newswire
Feb 26th, 2025
Fda Accepts Bla For Tlx250-Cdx (Zircaix®) For Kidney Cancer Imaging, Grants Priority Review

MELBOURNE, Australia, Feb. 26, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its breakthrough investigational kidney cancer PET[1] imaging agent TLX250-CDx (Zircaix®[2], 89Zr-DFO-girentuximab), granted a Priority Review and provided a PDUFA[3] date of 27 August 2025, paving the way for a U.S. commercial launch in 2025.If approved, TLX250-CDx will become the first commercially available imaging agent to accurately and non-invasively diagnose and characterize clear cell renal cell carcinoma (ccRCC), the most common and one of the most aggressive sub-types of kidney cancer. It works by specifically binding to carbonic anhydrase IX (CAIX), a validated target protein expressed on 95% of ccRCC cells to produce images with high tumor-to-background ratio and high intra- and inter-reader consistency.The BLA is based on Telix's successful global Phase 3 ZIRCON[4] study, which demonstrated a sensitivity of 86%, specificity of 87% and a positive predictive value (PPV) of 93% for ccRCC, including in very small, difficult-to-detect lesions[5]. The results of this study were published in The Lancet Oncology in September 2024, in a peer-reviewed manuscript by Professor Brian Shuch (University of California, Los Angeles, UCLA) and colleagues[6]. The paper outlines the critical unmet need for a new, non-invasive technique that can accurately detect and differentiate ccRCC from other renal masses in patients and concluded that TLX250-CDx meets this need and 'has the potential to be practice changing.'Kevin Richardson, Chief Executive Officer, Precision Medicine, said, "We are delighted that the FDA has accepted this BLA as it moves us one step closer to bringing our breakthrough product to patients

The Manila Times
Feb 13th, 2025
Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)

Telix to showcase urology pipeline at upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025).

PR Newswire
Feb 12th, 2025
Illuccix® Approved In The United Kingdom

MELBOURNE, Australia, Feb. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection).Illuccix is indicated in the UK for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, using PET. PSMA-PET imaging[2] represents a major advancement in prostate cancer management, largely replacing conventional imaging methods (bone scan, CT[3] scan) as the standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines highlight the superior accuracy of PSMA-PET for the staging of primary disease and evaluation of BCR/biochemical persistence (BCP)[4].Gary Cook, MD, Professor of Molecular Imaging at Kings College London School of Biomedical Engineering & Imaging Sciences, commented, "PSMA-PET supply shortages in the UK and Europe have escalated over the past 12 months as demand increases, which has led to delays for men in urgent need of a scan to direct clinical management. It is great news that Telix can now help address this unmet need and improve equity of access in the UK through their Illuccix imaging agent and network distribution model."Raphaël Ortiz, Chief Executive Officer, Telix International added, "PSMA-PET imaging is one of the most important developments in prostate cancer detection in recent years and we are delighted that we can now bring Illuccix to physicians and their patients across the UK. A key advantage of Illuccix is that the radioisotope (gallium-68) can be produced using a generator locally, taking just a few minutes with minimal equipment

PR Newswire
Jan 22nd, 2025
ImaginAb's Biologics Platform Acquired by Telix

ImaginAb, Inc. has agreed to sell its next-generation therapeutic candidates, biologics technology platform, and research facility to Telix Pharmaceuticals. Post-transaction, ImaginAb will focus on its CD8 ImmunoPET, in Phase 2 trials, and its prostate cancer imaging agent. The sale allows Telix to explore new disease areas with radiotherapeutic technology. Jefferies LLC and Stifel, Nicolaus & Company advised on the transaction.

PR Newswire
Jan 16th, 2025
Illuccix® Receives European Approval

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection), which was submitted in Europe via a decentralized procedure (DCP). This significant milestone follows the issuance of the Final Assessment Report from the German Competent Authority BfArM[2] as Reference Member State (RMS). Through the DCP, the RMS and all 18 European Economic Area (EEA) Concerned Member States (CMS)[3] agree that Illuccix should receive marketing authorization. The DCP regulatory process will now transition into an administrative national phase to implement authorizations to facilitate commercial launch in each country[4]. Kevin Richardson, Chief Executive Officer, Telix Precision Medicine commented, "We are delighted by this positive outcome, setting the stage for a European commercial launch of Illuccix

Recently Posted Jobs

Sign up to get curated job recommendations

Telix Pharmaceuticals is Hiring for 24 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Telix Pharmaceuticals's jobs every few hours, so check again soon! Browse all jobs →